Abstract:243 Background: The phosphatidylinositol-3-kinase (PI3K)/AKT and mammalian target of rapamycin (mTOR) signaling pathway dysregulation is a prominent feature of pancreatic ductal adenocarcinoma (PDAC). Gemcitabine (GEM), a standard systemic treatment for PDAC, has limited clinical benefits. The present study investigated the effects of NVP-BEZ235 (BEZ235), a novel dual PI3K/mTOR inhibitor, in combination with gemcitabine and endothelial monocyte activating polypeptide II (EMAP) in experimental PDAC. Methods: Protein expression and cell proliferation were analyzed by Western blotting and WST-1 assay. Animal experiments were performed in murine xenografts. Results: BEZ235 inhibited phospho-AKT (Ser473) and phospho-mTOR (Ser2448) expression in PDAC (AsPC-1), endothelial (HUVECs) and fibroblast (WI-38) cells. NVP-BEZ235 also caused a significant dephosphorylation of downstream mTORC1 target proteins phospho-p70 S6K (Thr389) and phospho-4E-BP1 (Thr37/46). In vitro 72-hour proliferation of four PDAC cell lines was significantly inhibited by BEZ235. Additive effects on proliferation inhibition were observed in the BEZ235 and GEM combination in PDAC cells and in combination of BEZ235 or EMAP with gemcitabine in HUVECs and WI-38 cells. BEZ235, alone or in combination with GEM and EMAP, induced apoptosis in AsPC-1, HUVECs and WI-38 cells as observed by increased expression of cleaved poly (ADP-ribose) polymerase-1 (PARP-1) and caspase-3 proteins. PDAC in vivo therapy demonstrated that compared to controls (median survival: 16 days), animal survival increased after BEZ235 and EMAP therapy alone (both 21 days) and GEM monotherapy (28 days). Further increases in survival occurred in combination therapy groups BEZ235+GEM (30 days, p=0.007), BEZ235+EMAP (27 days, p=0.02), GEM+EMAP (31 days, p=0.001) and BEZ235+GEM +EMAP (33 days, p=0.004). Conclusions: BEZ235 has experimental PDAC antitumor activity in vitro and in vivo that can be enhanced in combination with cytotoxic (GEM) and antiendothelial (EMAP) agents. These findings demonstrate advantages of combination therapy strategies targeting multiple pathways in pancreatic cancer treatment.

NVP-BEZ235 Attenuated Cell Proliferation and Migration in the Squamous Cell Carcinoma of Oral Cavities and p70S6K Inhibition Mimics its Effect

The Synergistic Antitumor Effect of IL-6 Neutralization with NVP-BEZ235 in Hepatocellular Carcinoma

Cancer Therapy : Preclinical Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ 235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma

Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using Nvp-Bez235 As A Novel Therapeutic Approach in Human Ovarian Carcinoma

Effects of NVP-BEZ235 on the Proliferation, Migration, Apoptosis and Autophagy in HT-29 Human Colorectal Adenocarcinoma Cells.

Dual Phosphoinositide 3-Kinase/mammalian Target of Rapamycin Inhibitor NVP-BEZ235 Has a Therapeutic Potential and Sensitizes Cisplatin in Nasopharyngeal Carcinoma.

Effect of NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, on Chemotherapy and Antiangiogenic Response in Pancreatic Cancer.

Advances in anticancer effect of NVP-BEZ235 and its mechanism

NVP-BEZ235, Dual Phosphatidylinositol 3-Kinase/mammalian Target of Rapamycin Inhibitor, Prominently Enhances Radiosensitivity of Prostate Cancer Cell Line PC-3

The dual PI3K/mTOR inhibitor NVP-BEZ235 prevents epithelial–mesenchymal transition induced by hypoxia and TGF-β1

Dual inhibition of autophagy and PI3K/mTOR pathway as a potential therapeutic strategy against laryngeal squamous cell carcinoma

NVP-BEZ235, a Novel Dual PI3K/mTOR Inhibitor, Enhances the Radiosensitivity of Human Glioma Stem Cells in Vitro

The Combination of NVP-BEZ235 and Rapamycin Regulates Nasopharyngeal Carcinoma Cell Viability and Apoptosis Via the PI3K/AKT/mTOR Pathway

Dual PI3K/mTOR Inhibitor NVP-BEZ235-induced Apoptosis of Hepatocellular Carcinoma Cell Lines is Enhanced by Inhibitors of Autophagy

Augmentation of NVP-BEZ235's Anticancer Activity Against Human Lung Cancer Cells by Blockage of Autophagy.

Nidus Vespae Protein Inhibiting Proliferation of Hepg2 Hepatoma Cells Through Extracellular Signal-Regulated Kinase Signaling Pathways and Inducing G(1) Cell Cycle Arrest

The Combination of RAD001 and NVP-BEZ235 Exerts Synergistic Anticancer Activity Against Non-Small Cell Lung Cancer in Vitro and in Vivo

Inhibition of esophageal cancer growth through the suppression of PI3K/AKT/mTOR signaling pathway

A Novel Humanized Anti-Pd-1 Monoclonal Antibody Potentiates Therapy in Oral Squamous Cell Carcinoma.

Inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235

NVP-BEZ235 Inhibits Thyroid Cancer Growth by P53- Dependent/independent P21 Upregulation